logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
R

Rinath Jeselsohn

Harvard Medical School
H指数:39
被引数:6,273

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy

III期postMONARCH试验中，阿贝西利联合氟维司群与安慰剂联合氟维司群治疗既往接受过CDK4/6抑制剂联合内分泌治疗后进展的HR+、HER2-晚期乳腺癌的总体生存率

Annals of Oncology
IF65.4
2026-10-240
OA
Kevin Kalinsky; Seth A. Wander; Erika Hamilton; Stephanie L. Graff; Rinath Jeselsohn; Kyong Hwa Park; Umut Demirci; Miguel Martin; Rachel M. Layman; Sara A. Hurvitz; Sarah Sammons; Peter A. Kaufman; Elizabeth Ravenberg; Sasha Amdur; Lacey M. Litchfield; Giampaolo Bianchini
PROFET predicts continuous gene expression dynamics from scRNA-seq data to elucidate heterogeneity of cancer treatment responses

PROFET通过单细胞RNA测序数据预测连续基因表达动态，以阐明癌症治疗反应的异质性

Cell Systems
IF7.7
2026-08-280
PRE
Yu-Chen Cheng; Hyemin Gu; Thomas O. McDonald; Wenbo Wu; Shubham Tripathi; Cristina Guarducci; Douglas Russo; Daniel L. Abravanel; Madeline Bailey; Yue Wang; Yun Zhang; Yannis Pantazis; Herbert Levine; Rinath Jeselsohn; Markos A. Katsoulakis; Franziska Michor
Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer

定量HER2组织与血浆分析可预测曲妥珠单抗德鲁克替康对乳腺癌的活性

npj Precision Oncology
IF8
2026-03-130
OAAI
Paolo Tarantino; Se-Eun Kim; Melissa E. Hughes; Ross J. Kusmick; Kalie Smith; Fara Brasó-Maristany; Nay Nwe Nyein Chan; Laia Paré Brunet; Laura Alder; Diana Garcia-Cortes; Jorge Gomez Tejeda Zanudo; Alyssa M. Pereslete; Laura Noteware; Heather Moore; Amanda E. D. Van Swearingen; Tianyu Li; Hersh Gupta; Olivia D’Amico; Alba Martini; Stefania Morganti; Jennifer Spindel; Charmaine Cook; Christine McLaughlin; Kathrin Dvir; Ana C. Garrido-Castro; Sarah Sammons; Janet Files; Kerry Sendrick; Simone Buck; Deborah Dillon; Rinath Jeselsohn; Yvonne Y. Li; Andrew D. Cherniack; Patricia LoRusso; Maryam Lustberg; Rosario Vega- León; Francisco Pardo; Justin Davis; Claudius Mueller; Brian Corgiat; Giuseppe Curigliano; Carey K. Anders; Emanuel F. Petricoin; David L. Rimm; Aleix Prat; Nabihah Tayob; Nancy U. Lin; Sara M. Tolaney
Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer

雄激素受体表达和HER2-low转移性三阴性乳腺癌的免疫特征

npj Breast Cancer
IF7.6
2026-02-130
OA
Paolo Tarantino; Jaeyoon Cha; Busem Binboga Kurt; Xiangying Chu; Bojana Jovanović; Andrew Zhou; Melissa Hughes; Douglas Russo; Molly DiLullo; Eileen Wrabel; Rinath Jeselsohn; Nancy U. Lin; Jamie Carter; Yisang Serenity Chen; Tianyu Li; Nabihah Tayob; Elizabeth A. Mittendorf; Stuart J. Schnitt; Shom Goel; Sara M. Tolaney
Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer

早期激素受体阳性乳腺癌在抗PD-1和化疗治疗期间细胞的重编程

Nature Communications
IF15.7
2025-11-280
OAAI
Jingxin Fu; Adrienne G. Waks; Erica Pimenta; Breanna Titchen; Kevin Bi; Sabrina Camp; Theodora Pappa; Tanya Keenan; Erin Shannon; Sébastien Vigneau; Meredith Bemus; Anwesha Nag; Aaron R. Thorner; Jihye Park; Molly DiLullo; Eileen Wrabel; Rinath Jeselsohn; Elizabeth A. Mittendorf; Daniel L. Abravanel; Sara M. Tolaney; Eliezer M. Van Allen
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial

疗效、安全性及预测性生物标志物：nab-paclitaxel联合pembrolizumab治疗激素受体阳性乳腺癌的随机试点试验

Nature Communications
IF15.7
2025-11-280
OAAI
Adrienne G. Waks; Jingxin Fu; Xiangying Chu; Busem Binboga Kurt; Tianyu Li; Thomas M. Kuntz; Yizhuo Shen; David Yang; Kevin Meli; Brendan Reardon; Jihye Park; Ann Partridge; Daniel Abravanel; Rinath Jeselsohn; Eileen Wrabel; Jillian Alberti; Molly DiLullo; Serenity Chen; Ayesha Mohammed-Abreu; Xiaopeng Sun; Justin M. Balko; Miranda Kleijn; William Audeh; Xochitl C. Morgan; Ian E. Krop; Nabihah Tayob; Eliezer M. Van Allen; Elizabeth A. Mittendorf; Sara M. Tolaney
Axillary Management and Outcomes After Neoadjuvant Endocrine Therapy in the Randomized PELOPS Trial

腋窝处理及新辅助内分泌疗法后的结局：PELOPS 随机试验研究

Annals of Surgical Oncology
IF3.5
2025-11-230
PRE
Anna Weiss; Qingchun Jin; Nabihah Tayob; Eileen Wrabel; Michelle DeMeo; Jamie Carter; Michael Constantine; Meredith Faggen; Caroline Block; Mary Anne Fenton; K. M. Steve Lo; Thomas Openshaw; Denise Yardley; Laura Kennedy; Isabelle Bedrosian; Elizabeth A. Mittendorf; Rinath Jeselsohn; Otto Metzger Filho; Tari A. King
Tamoxifen induces PI3K activation in uterine cancer

他莫昔芬诱导子宫癌中PI3K的激活

Nature Genetics
IF0
2025-08-220
OAAI
Kirsten Kübler; Agostina Nardone; Shankara Anand; Daniel Gurevich; Jianjiong Gao; Marjolein Droog; Francisco Hermida-Prado; Tara Akhshi; Ariel Feiglin; Avery S. Feit; Gabriella Cohen Feit; Gwen Dackus; Matthew Pun; Yanan Kuang; Justin Cha; Mendy Miller; Sebastian Gregoricchio; Mirthe Lanfermeijer; Sten Cornelissen; William J. Gibson; Cloud P. Paweletz; Eliezer M. Van Allen; Flora E. van Leeuwen; Petra M. Nederlof; Quang-Dé Nguyen; Marian J. E. Mourits; Milan Radovich; Ignaty Leshchiner; Chip Stewart; Ursula A. Matulonis; Wilbert Zwart; Yosef E. Maruvka; Gad Getz; Rinath Jeselsohn
Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study☆

Prosigna检测试剂盒对早期HR阳性/HER2阴性乳腺癌患者新辅助治疗决策的影响：一项单中心前瞻性观察研究☆

ESMO Open
IF8.3
2025-07-250
OAAI
C. Corti; X. Chu; P. Exman; D.M. Kline; N.M. Priedigkeit; E.L. Mayer; A.G. Waks; M.E. Hughes; D.L. Abravanel; A. Giordano; G. Curigliano; N.U. Lin; T.A. King; R.M. Jeselsohn; D.K. Manning; D.A. Dillon; E.A. Mittendorf; N. Tayob; S.M. Tolaney
Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer☆

循环肿瘤DNA突变景观和进展后使用CDK4/6抑制剂的动态变化：PACE II期临床试验中转移性HR阳性/HER2阴性乳腺癌☆

ESMO Open
IF8.3
2025-07-250
OAAI
R. Jeselsohn; J. Fu; Y. Ren; R. Mahtani; C. Ma; A. DeMichele; M. Cristofanilli; J. Meisel; K.D. Miller; Y. Abdou; E.C. Riley; R. Qamar; P. Sharma; S. Reid; N. Ko; Y. Liu; E. Gauthier; H.J. Burstein; M. DeMeo; M. Regan; S.M. Tolaney; E.L. Mayer
MUC1-C dependency in drug resistant HR+/HER2- breast cancer identifies a new target for antibody-drug conjugate treatment

MUC1-C依赖性在药物耐药的HR+/HER2-乳腺癌中确定了一种新型抗体药物偶联物治疗靶点

NPJ BREAST CANCER
IF7.6
2025-04-260
OA
Nakashoji, Ayako; Bhattacharya, Atrayee; Ozawa, Hiroki; Haratake, Naoki; Shigeta, Keisuke; Fushimi, Atsushi; Yamashita, Nami; Matsui, Akira; Kure, Shoko; Kameyama, Tomoe; Takeuchi, Makoto; Fukuda, Kazumasa; Yokoe, Takamichi; Nagayama, Aiko; Hayahsida, Tetsu; Kitagawa, Yuko; Liu, Renyan; Giordano, Antonio; Jeselsohn, Rinath; Shapiro, Geoffrey I.; Kufe, Donald
Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2

HER2-negative乳腺癌的分子表征揭示了一个具有17q12缺失和ERBB2杂合性缺失的独特患者亚组

ESMO OPEN
IF8.3
2025-02-010
PRE
Qiu, X.; Tarantino, P.; Li, R.; Grinshpun, A.; Gupta, H.; Hughes, M. E.; Kirkner, G.; Scholl, L.; Johnson, B. E.; Meyerson, M.; Cherniack, A. D.; Jiang, Y.; Zhou, N.; Lin, N. U.; Long, H. W.; Tolaney, S. M.; Jeselsohn, R.

研究方向

暂未获取到该数据
M
Myles Brown
H 指数:127论文数:913被引数:8.4万
S
Sara M. Tolaney
H 指数:83论文数:1,341被引数:3.6万
R
Rachel Schiff
H 指数:84论文数:609被引数:2.4万
A
Agostina Nardone
H 指数:20论文数:328被引数:2,074
M
Melissa E. Hughes
H 指数:40论文数:365被引数:7,200
X
Xiaoyong Fu
H 指数:37论文数:228被引数:5,508
C
Carmine De Angelis
H 指数:39论文数:375被引数:6,723
N
Nancy U. Lin
H 指数:95论文数:1,074被引数:4.2万
E
Eric P. Winer
H 指数:170论文数:1,624被引数:12.9万
M
Mothaffar F. Rimawi
H 指数:52论文数:509被引数:1.0万